X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
humans (3) 3
index medicus (3) 3
male (3) 3
aged (2) 2
cancer (2) 2
disease-free survival (2) 2
female (2) 2
middle aged (2) 2
neoplasm staging (2) 2
oncology (2) 2
adult (1) 1
antigens, cd20 - immunology (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
anus neoplasms - drug therapy (1) 1
anus neoplasms - immunology (1) 1
anus neoplasms - pathology (1) 1
anus neoplasms - radiotherapy (1) 1
autografts (1) 1
b-cell lymphoma (1) 1
biopsy, needle (1) 1
blood (1) 1
candidates (1) 1
carcinoma, large cell - drug therapy (1) 1
carcinoma, large cell - pathology (1) 1
carcinoma, large cell - secondary (1) 1
carcinoma, squamous cell - drug therapy (1) 1
carcinoma, squamous cell - immunology (1) 1
carcinoma, squamous cell - pathology (1) 1
carcinoma, squamous cell - radiotherapy (1) 1
care and treatment (1) 1
cd20 antigen (1) 1
cetuximab - administration & dosage (1) 1
chemoradiation (1) 1
chemoradiotherapy (1) 1
chemotherapy (1) 1
cisplatin (1) 1
cisplatin - administration & dosage (1) 1
colony-stimulating factor (1) 1
combination (1) 1
combined modality (1) 1
conventional chemoradiotherapy (1) 1
cytarabine (1) 1
cytarabine - administration & dosage (1) 1
cytarabine - adverse effects (1) 1
cytarabine - therapeutic use (1) 1
cytosine (1) 1
cytosine arabinoside (1) 1
dexamethasone (1) 1
dexamethasone - administration & dosage (1) 1
dexamethasone - adverse effects (1) 1
dexamethasone - therapeutic use (1) 1
disease progression (1) 1
diseases (1) 1
drug administration schedule (1) 1
drug-related side effects and adverse reactions - epidemiology (1) 1
drug-related side effects and adverse reactions - etiology (1) 1
eosinophilia - pathology (1) 1
eosinophilia - therapy (1) 1
etoposide (1) 1
fatal outcome (1) 1
filgrastim (1) 1
fluorouracil - administration & dosage (1) 1
follow-up studies (1) 1
gemcitabine (1) 1
granulocyte colony-stimulating factor - administration & dosage (1) 1
granulocyte colony-stimulating factor - adverse effects (1) 1
granulocyte colony-stimulating factor - therapeutic use (1) 1
head (1) 1
hematology (1) 1
high-dose cytarabine (1) 1
hodgkin's disease (1) 1
hpv (1) 1
human-papillomavirus infection (1) 1
immunocompetence (1) 1
immunohistochemistry (1) 1
kaplan-meier estimate (1) 1
large-cell-carcinoma (1) 1
lung neoplasms - drug therapy (1) 1
lung neoplasms - pathology (1) 1
lymphocytes b (1) 1
lymphoma (1) 1
lymphoma, b-cell - drug therapy (1) 1
lymphoma, b-cell - immunology (1) 1
lymphoma, b-cell - mortality (1) 1
lymphoma, b-cell - pathology (1) 1
lymphomas (1) 1
magnetic resonance imaging (1) 1
medical research (1) 1
mitomycin (1) 1
neoplasm invasiveness - pathology (1) 1
neuropathy (1) 1
oncology, experimental (1) 1
organoplatinum compounds - administration & dosage (1) 1
organoplatinum compounds - adverse effects (1) 1
organoplatinum compounds - therapeutic use (1) 1
original reports (1) 1
oxaliplatin (1) 1
palliative care - methods (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e18531 - e18531
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 10/2017, Volume 92, Issue 10, pp. 1004 - 1010
Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous... 
B-CELL LYMPHOMA | ETOPOSIDE | PHASE-II | HIGH-DOSE CYTARABINE | CANDIDATES | HEMATOLOGY | SALVAGE REGIMEN | CHEMOTHERAPY | GEMCITABINE | TRANSPLANTATION | Recombinant Proteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Cytarabine - adverse effects | Recombinant Proteins - adverse effects | Filgrastim | Rituximab - therapeutic use | Organoplatinum Compounds - administration & dosage | Lymphoma, B-Cell - immunology | Female | Lymphoma, B-Cell - drug therapy | Rituximab - adverse effects | Granulocyte Colony-Stimulating Factor - adverse effects | Antigens, CD20 - immunology | Dexamethasone - administration & dosage | Lymphoma, B-Cell - mortality | Drug Administration Schedule | Polyethylene Glycols | Kaplan-Meier Estimate | Drug-Related Side Effects and Adverse Reactions - etiology | Granulocyte Colony-Stimulating Factor - therapeutic use | Cytarabine - administration & dosage | Recombinant Proteins - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Rituximab - administration & dosage | Disease-Free Survival | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, B-Cell - pathology | Aged | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Care and treatment | Relapse | Pyrimidines | Dexamethasone | Cytarabine | Oncology, Experimental | Stem cells | Research | Cancer | Diseases | Steroids | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e23145 - e23145
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.